Loperamide/simethicone in the intestinal tract, making them easier to pass. Simethicone is not absorbed from the gastrointestinal tract so there are no systemic side effects. Anti-diarrheal medications should be avoided if diarrhea is secondary to an infection. Avoid using such products in the presence of fever, black stools, bloody stools, or stools containing mucus. Loperamide/simethicone Loperamide/simethicone is combination medication marketed under the trade name Imodium Multi-Symptom Relief (formerly Imodium A-D Advanced) used to treat diarrhea and gas simultaneously. It is manufactured by the McNeil Consumer Healthcare Division of McNeil PPC, Inc. Loperamide is a μ-opioid receptor agonist that works in the
Intention-to-treat analysis be providing benefits if one merely compares the condition before and after the treatment for only those who finish the study (ignoring those who were enrolled originally, but have since been excluded or dropped out). Medical investigators often have difficulties in completing ITT analysis because of clinical trial issues like missing data or poor treatment protocol adherence. To address some of these issues, many clinical trials have excluded participants after the random assignment in their analysis, which is often referred to as "modified intention-to-treat analysis" or mITT. Trials employing mITT have been linked to industry sponsorship and conflicts of interest